Galectin Therapeutics Inc. (GALT)

NASDAQ: GALT · IEX Real-Time Price · USD
2.390
-0.020 (-0.83%)
At close: Mar 28, 2024, 4:00 PM
2.400
+0.010 (0.42%)
After-hours: Mar 28, 2024, 7:43 PM EDT

Company Description

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases.

Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration.

The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011.

Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Galectin Therapeutics Inc.
Galectin Therapeutics logo
Country United States
Founded 2000
Industry Biotechnology
Sector Healthcare
Employees 12
CEO Joel Lewis

Contact Details

Address:
4960 Peachtree Industrial Boulevard, Suite 240
Norcross, Georgia 30071
United States
Phone 678-620-3186
Website galectintherapeutics.com

Stock Details

Ticker Symbol GALT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001133416
CUSIP Number 363225202
ISIN Number US3632252025
Employer ID 04-3562325
SIC Code 2834

Key Executives

Name Position
Joel Lewis President, Chief Executive Officer and Director
Jack W. Callicutt CPA Chief Financial Officer, Treasurer and Corporate Secretary
Dr. Pol F. Boudes M.D., Ph.D. Chief Medical Officer
Robert Tritt General Counsel
Jeff Katstra Head of CMC and Pharmaceutical Development
Beth Knowles Executive Assistant and Officer Manager

Latest SEC Filings

Date Type Title
Dec 11, 2023 8-K Current Report
Dec 7, 2023 8-K Current Report
Dec 1, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 13, 2023 8-K/A [Amend] Current report
Nov 13, 2023 8-K Current Report
Nov 13, 2023 10-Q Quarterly Report
Oct 6, 2023 ARS Filing
Oct 6, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Oct 6, 2023 DEF 14A Other definitive proxy statements
Sep 11, 2023 144 Filing